Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3079694 | 0.90 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL5943360 | 0.89 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL25167616 | 0.87 | ALDH1A1 (0.51) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL29347075 | 0.87 | ALDH1A1 (0.51) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL29991029 | 0.87 | ALDH1A1 (0.51) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL20209799 | 0.85 | TDP1 (0.53) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL3498873 | 0.84 | ALDH1A1 (0.59) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL43748 | 0.84 | ALDH1A1 (0.63) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL1177836 | 0.83 | ALDH1A1 (0.73) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL22170234 | 0.81 | TDP1 (0.49) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582722-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-12-25 | — | — | US | disclosed |
| EP-4650348-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2025-11-19 | — | — | EP | disclosed |
| EP-4561585-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION, AND PREVENTION OF ECTOPIC CALCIFICATION | Sanifit Therapeutics S.A. (ES) | 2025-06-04 | — | — | EP | disclosed |
| CN-119855595-A | IP4-4,6 substituted derivative compounds for treating ectopic calcification, inhibiting progression and preventing ectopic calcification | 萨尼菲特治疗有限公司 | 2025-04-18 | — | — | CN | disclosed |
| WO-2024094150-A1 | NLRP3 INFLAMMASOME INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-05-10 | — | — | WO | disclosed |
| US-20240109924-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | VIFOR (INTERNATIONAL) LTD. (CH) | 2024-04-04 | — | — | US | disclosed |
| CN-117693502-A | Compounds for inhibiting or degrading ITK, compositions comprising the same, methods of making the same, and methods of using the same | 纽力克斯治疗公司 | 2024-03-12 | — | — | CN | disclosed |
| WO-2024023359-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION, AND PREVENTION OF ECTOPIC CALCIFICATION | SANIFIT THERAPEUTICS, S.A. (ES) | 2024-02-01 | — | — | WO | disclosed |
| EP-4284809-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | Sanifit Therapeutics S.A. (ES) | 2023-12-06 | — | — | EP | disclosed |
| US-6890513-B2 | Metal-carborane complexes for radioimaging and radiotherapy and methods for their preparation | MCMASTER UNIVERSITY (CA) | 2005-05-10 | — | — | US | disclosed |
| WO-2004082613-A2 | 2,4-DIAMINO-5-[5’-SUBSTITUTED-BENZYL] PYRIMIDINES AND 2,4-DIAMINO-6-[5’-SUBSTITUTED-BENZYL] QUINAZOLINES | DANA FARBER CANCER INSTITUTE (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
| WO-2004033419-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | ABBOTT LABORATORIES (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20030068271-A1 | Metal-carborane complexes for radioimaging and radiotherapy and methods for their preparation | MCMASTER UNIVERSITY (CA) | 2003-04-10 | — | — | US | disclosed |
| EP-0874808-B1 | BIPHENYL HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LAB (US) | 2003-04-09 | — | — | EP | disclosed |
| EP-0874808-A1 | BIPHENYL HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | Abbott Laboratories (US) | 1998-11-04 | — | — | EP | disclosed |
| US-5665777-A | ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 1997-09-09 | — | — | US | disclosed |
| WO-1997018188-A1 | BIPHENYL HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LABORATORIES (US) | 1997-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | ALDH1A1 3463/4885MAPK1 4534/4885L3MBTL1 2706/4885 |
| US-20240109924-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | IPO4, TPX2, IPO9 | ALDH1A1 4700/4885MAPK1 4308/4885L3MBTL1 3016/4885 |
| US-12582722-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | PSMB2, PSME3, PSMB3 | ALDH1A1 4614/4885MAPK1 1571/4885L3MBTL1 1179/4885 |
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | CRBN, CUL1, CBL | ALDH1A1 579/4885MAPK1 3214/4885L3MBTL1 1583/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | ALDH1A1 3463/4885MAPK1 4534/4885L3MBTL1 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.